Lumos Diagnostics to provide US FebriDx update at quarterly results briefing

Health Pharma & Biotech Written by: Jonathan Jackson 21:38 Sun 18 Oct 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Jonathan Jackson Jonathan Jackson is an experienced writer and editor. Over the past 20 years, he has worked in print and digital media across several business and finance titles amd is currently the Australian news editor at Proactive Investors covering the latest news for ASX listed companies as well as current financial trends. He was previously managing editor with Business First magazine, Wealth Creator Magazine and StocksDigital. Jonathan has interviewed some of the world's top CEOs and covered... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Lumos Diagnostics Holdings Ltd ( ASX:LDX OTC:LDXHF ) View Price & Profile Lumos Diagnostics to provide US FebriDx update at quarterly results briefing Published: 21:38 18 Oct 2026 EDT Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) will provide a US commercial update on FebriDx at an investor briefing on October 27, following the planned release of its September-quarter financial results. The rapid diagnostics company intends to report its results for the three months ended September 30, 2026, representing the first quarter of its 2027 financial year, with a shareholder webinar scheduled for 11am AEDT that day. Management to outline quarterly performance Chair Sam Lanyon, chief executive officer Doug Ward, chief financial officer Barrie Lambert and chief commercial officer Paul Kase will lead the briefing. Management will present an overview of the financial results and discuss FebriDx’s commercial activities in the US, followed by a question-and-answer session. Shareholders and investors can register in advance through the webinar link below. Access details will be sent by email once registration is complete. https://us02web.zoom.us/webinar/register/WN_1ImXEdmvShqthlL1UxNllw About Lumos Diagnostics Lumos develops and manufactures rapid point-of-care diagnostic technologies to help healthcare professionals diagnose and manage medical conditions. The company provides customised diagnostic test development and manufacturing services, alongside proprietary digital reader platforms. It also develops, manufactures and commercialises its own branded point-of-care tests targeting infectious and inflammatory diseases. Continue reading